- Home
- CWAN vs LEGN Comparison
CWAN vs LEGN Comparison
Compare CWAN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWAN
- LEGN
- Stock Information
- Founded
- CWAN 2004
- LEGN 2014
- Country
- CWAN United States
- LEGN United States
- Employees
- CWAN N/A
- LEGN N/A
- Industry
- CWAN Computer Software: Prepackaged Software
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CWAN Technology
- LEGN Health Care
- Exchange
- CWAN Nasdaq
- LEGN Nasdaq
- Market Cap
- CWAN 6.1B
- LEGN 5.4B
- IPO Year
- CWAN 2021
- LEGN 2020
- Fundamental
- Price
- CWAN $22.14
- LEGN $35.64
- Analyst Decision
- CWAN Buy
- LEGN Strong Buy
- Analyst Count
- CWAN 10
- LEGN 13
- Target Price
- CWAN $31.50
- LEGN $75.17
- AVG Volume (30 Days)
- CWAN 4.6M
- LEGN 2.0M
- Earning Date
- CWAN 07-30-2025
- LEGN 08-08-2025
- Dividend Yield
- CWAN N/A
- LEGN N/A
- EPS Growth
- CWAN N/A
- LEGN N/A
- EPS
- CWAN 1.71
- LEGN N/A
- Revenue
- CWAN $475,948,000.00
- LEGN $728,303,000.00
- Revenue This Year
- CWAN $63.43
- LEGN $65.49
- Revenue Next Year
- CWAN $29.94
- LEGN $53.76
- P/E Ratio
- CWAN $12.92
- LEGN N/A
- Revenue Growth
- CWAN 23.21
- LEGN 112.46
- 52 Week Low
- CWAN $17.63
- LEGN $27.34
- 52 Week High
- CWAN $35.71
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- CWAN 46.90
- LEGN 57.79
- Support Level
- CWAN $21.39
- LEGN $32.42
- Resistance Level
- CWAN $22.47
- LEGN $36.91
- Average True Range (ATR)
- CWAN 0.67
- LEGN 1.42
- MACD
- CWAN 0.01
- LEGN 0.02
- Stochastic Oscillator
- CWAN 60.82
- LEGN 67.58
About CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.